UPDATE: UBS Investment Research Reiterates Buy Rating, Raises PT on Mylan Following Investor Day

In a report published Friday, UBS Investment Research analyst Marc Goodman reiterated a Buy rating on Mylan MYL, and raised the price target from $36.00 to $39.00. In the report, UBS Investment Research noted, “Mgt did a good job detailing key drivers (injectables, respiratory, ARV, biologics, Copaxone, strong pipeline, geographical expansion) of its 2018 guidance. New datapts incl. a Seretide MDI generics program, Advair P3 starts in 2H13, R&D spend of $2.8B planned for next 5 yrs, tax rate in 2018 down to 22%, injectables sales of $350M in 2013, $700M in 2014 and $1B in 2016, Herceptin is in P3 trials, generic Lantus starts P3 in 1H14, EpiPen generics in 2015 guidance and no US biologics incl. in the 5 yr plan.” Mylan closed on Thursday at $33.98.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorPrice TargetAnalyst RatingsMarc GoodmanUBS Investment Research
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!